Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SB-773812 dose-ranging study in adults with schizophrenia
2005-002883-27Phase 2Completed
- Sponsor
- GSK
- Start
- Oct 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of SB-773812 in schizophrenia (3 arms), sponsored by GSK. Primary endpoint: Change from baseline in PANSS total score at Week 6. Started Oct 2005; status: completed.
02
Drugs
SB-773812
03
Conditions
schizophrenia
Beyond the preview
Go deeper on 2005-002883-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-002883-27.